{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HER-2+Positive+Advanced+Solid+Tumors&page=2",
    "query": {
      "condition": "HER-2 Positive Advanced Solid Tumors",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HER-2+Positive+Advanced+Solid+Tumors&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-07-23T00:16:58.562Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05054374",
      "title": "A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Breast Cancer Stage IV",
        "HER2-negative Breast Cancer",
        "Solid Carcinoma",
        "MEK1 Gene Mutation",
        "MEK2 Gene Mutation",
        "Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Mirdametinib",
          "type": "DRUG"
        },
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2021-09-14",
      "completion_date": "2023-10-26",
      "has_results": true,
      "last_update_posted_date": "2025-05-23",
      "last_synced_at": "2026-07-23T00:16:58.562Z",
      "location_count": 4,
      "location_summary": "Middletown, New Jersey • Commack, New York • Harrison, New York + 1 more",
      "locations": [
        {
          "city": "Middletown",
          "state": "New Jersey"
        },
        {
          "city": "Commack",
          "state": "New York"
        },
        {
          "city": "Harrison",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05054374"
    },
    {
      "nct_id": "NCT07288359",
      "title": "Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced HR+/HER2- Breast Cancer",
        "Advanced CCNE1-amplified Solid Tumors",
        "Metastatic Castration-resistant Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "GVV858",
          "type": "DRUG"
        },
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        },
        {
          "name": "Letrozole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 205,
      "start_date": "2025-12-29",
      "completion_date": "2031-05-09",
      "has_results": false,
      "last_update_posted_date": "2026-07-07",
      "last_synced_at": "2026-07-23T00:16:58.562Z",
      "location_count": 2,
      "location_summary": "Nashville, Tennessee • San Antonio, Texas",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07288359"
    },
    {
      "nct_id": "NCT00741260",
      "title": "Study Evaluating The Combination Of Neratinib And Capecitabine In Solid Tumors And Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Neratinib",
          "type": "DRUG"
        },
        {
          "name": "Capecitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Puma Biotechnology, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 105,
      "start_date": "2008-12-09",
      "completion_date": "2018-06",
      "has_results": true,
      "last_update_posted_date": "2018-09-05",
      "last_synced_at": "2026-07-23T00:16:58.562Z",
      "location_count": 12,
      "location_summary": "Mobile, Alabama • Long Beach, California • Los Angeles, California + 9 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Post Falls",
          "state": "Idaho"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00741260"
    },
    {
      "nct_id": "NCT04492488",
      "title": "A Study of MRG002 in Patients with HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumors",
        "Advanced or Metastatic Gastric Cancer",
        "Advanced or Metastatic Gastroesophageal Junction Cancer"
      ],
      "interventions": [
        {
          "name": "MRG002",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shanghai Miracogen Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 129,
      "start_date": "2021-05-24",
      "completion_date": "2024-12-31",
      "has_results": false,
      "last_update_posted_date": "2024-10-22",
      "last_synced_at": "2026-07-23T00:16:58.562Z",
      "location_count": 2,
      "location_summary": "Orange, California • Houston, Texas",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04492488"
    },
    {
      "nct_id": "NCT01576666",
      "title": "Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Dose Escalation",
        "Safety",
        "Preliminary Efficacy",
        "Advanced Solid Tumors",
        "Metastatic Breast Cancer",
        "Advanced Pancreatic Adenocarcinoma",
        "Metastatic Colorectal Cancer",
        "Recurrent Glioblastoma Multiforme",
        "Gastric Cancer",
        "Gastroesophageal Junction Cancer",
        "Triple Negative Metastatic Breast Cancer",
        "Hormone Receptor Positive (ER+/PR+, and Her2-) Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "LDE225",
          "type": "DRUG"
        },
        {
          "name": "BKM120",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 120,
      "start_date": "2012-07",
      "completion_date": "2015-04",
      "has_results": false,
      "last_update_posted_date": "2020-12-19",
      "last_synced_at": "2026-07-23T00:16:58.562Z",
      "location_count": 13,
      "location_summary": "Los Angeles, California • San Francisco, California • Tampa, Florida + 9 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01576666"
    },
    {
      "nct_id": "NCT00526045",
      "title": "Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Hematologic Neoplasms"
      ],
      "interventions": [
        {
          "name": "AUY922 2 mg/m2",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 117,
      "start_date": "2007-07",
      "completion_date": "2012-04",
      "has_results": false,
      "last_update_posted_date": "2020-12-17",
      "last_synced_at": "2026-07-23T00:16:58.562Z",
      "location_count": 7,
      "location_summary": "Los Angeles, California • Augusta, Georgia • Boston, Massachusetts + 4 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Las Vegas",
          "state": "Nevada"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00526045"
    },
    {
      "nct_id": "NCT04872166",
      "title": "A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumor",
        "Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "BTX-A51",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Edgewood Oncology Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 112,
      "start_date": "2021-06-07",
      "completion_date": "2027-05",
      "has_results": false,
      "last_update_posted_date": "2025-01-30",
      "last_synced_at": "2026-07-23T00:16:58.562Z",
      "location_count": 6,
      "location_summary": "Lake Mary, Florida • Sarasota, Florida • Cincinnati, Ohio + 2 more",
      "locations": [
        {
          "city": "Lake Mary",
          "state": "Florida"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04872166"
    },
    {
      "nct_id": "NCT06625775",
      "title": "Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor, Adult",
        "Metastatic Breast Cancer",
        "Advanced Breast Cancer",
        "HER2 Mutation-Related Tumors",
        "HER2-positive Metastatic Breast Cancer",
        "KRAS Mutant Metastatic Colorectal Cancer",
        "Metastatic Lung Cancer",
        "Metastatic Colorectal Cancer",
        "Advanced Lung Cancer",
        "HR-positive, HER2-negative Advanced Breast Cancer",
        "HER2-positive Advanced Breast Cancer"
      ],
      "interventions": [
        {
          "name": "BBO-10203",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab",
          "type": "DRUG"
        },
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        },
        {
          "name": "Ribociclib",
          "type": "DRUG"
        },
        {
          "name": "FOLFOX",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 392,
      "start_date": "2024-10-29",
      "completion_date": "2028-11",
      "has_results": false,
      "last_update_posted_date": "2026-06-23",
      "last_synced_at": "2026-07-23T00:16:58.562Z",
      "location_count": 19,
      "location_summary": "Duarte, California • Los Angeles, California • San Diego, California + 13 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06625775"
    },
    {
      "nct_id": "NCT05768139",
      "title": "First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Solid Tumors, Adult"
      ],
      "interventions": [
        {
          "name": "STX-478",
          "type": "DRUG"
        },
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        },
        {
          "name": "Ribociclib",
          "type": "DRUG"
        },
        {
          "name": "Palbociclib",
          "type": "DRUG"
        },
        {
          "name": "Letrozole",
          "type": "DRUG"
        },
        {
          "name": "Anastrozole",
          "type": "DRUG"
        },
        {
          "name": "Exemestane",
          "type": "DRUG"
        },
        {
          "name": "Tamoxifen",
          "type": "DRUG"
        },
        {
          "name": "Abemaciclib",
          "type": "DRUG"
        },
        {
          "name": "Imlunestrant",
          "type": "DRUG"
        },
        {
          "name": "Metformin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 880,
      "start_date": "2023-04-17",
      "completion_date": "2030-07",
      "has_results": false,
      "last_update_posted_date": "2026-07-07",
      "last_synced_at": "2026-07-23T00:16:58.562Z",
      "location_count": 28,
      "location_summary": "Los Angeles, California • San Francisco, California • Aurora, Colorado + 22 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Lake Mary",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05768139"
    },
    {
      "nct_id": "NCT06241456",
      "title": "FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumor"
      ],
      "interventions": [
        {
          "name": "FT825",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Bendamustine",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Cetuximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Fate Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 351,
      "start_date": "2024-01-05",
      "completion_date": "2044-05-01",
      "has_results": false,
      "last_update_posted_date": "2025-12-09",
      "last_synced_at": "2026-07-23T00:16:58.562Z",
      "location_count": 14,
      "location_summary": "Gilbert, Arizona • La Jolla, California • New Haven, Connecticut + 11 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06241456"
    }
  ]
}